Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 18/20 | 0.41 |
| ▸ | CDK9 | P50750 | 18/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22476358 | 0.83 | CCNT1 (0.55) | CCNT1CDK9 | |
| SCHEMBL30603869 | 0.83 | CCNT1 (0.55) | CCNT1CDK9 | |
| SCHEMBL29110613 | 0.81 | DHFR (0.44) | CCNT1CDK9BTK | |
| SCHEMBL30606972 | 0.74 | SMN1; SMN2 (0.38) | BTKSMYD3 | |
| SCHEMBL29684579 | 0.73 | SMN1; SMN2 (0.40) | BTK | |
| SCHEMBL29650110 | 0.72 | LMNA (0.47) | — | |
| SCHEMBL29948559 | 0.72 | CNR1 (0.50) | — | |
| SCHEMBL5005001 | 0.71 | CCNT1 (0.58) | CCNT1CDK9BTK | |
| SCHEMBL8369432 | 0.70 | NPC1 (0.48) | SMYD3 | |
| SCHEMBL7826168 | 0.69 | DRD4 (0.41) | SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793575-B2 | Oxoisoquinoline derivatives | CARNA BIOSCIENCES, INC. (JP) | 2020-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793575-B2 | Oxoisoquinoline derivatives | BCL6, BCL6B, BCL3 | CCNT1 753/4885CDK9 1462/4885BTK 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.